Journal Mobile Options
Table of Contents
Vol. 209, No. 4, 2004
Issue release date: 2004
Dermatology 2004;209:314–320
(DOI:10.1159/000080855)

Influence of Pimecrolimus Cream 1% on Different Morphological Signs of Eczema in Infants with Atopic Dermatitis

Breuer K. · Braeutigam M. · Kapp A. · Werfel T.
aDepartment of Dermatology and Allergology, Hannover Medical University, Hannover, and bNovartis Pharma GmbH, Clinical Research, Nürnberg, Germany

Individual Users: Register with Karger Login Information

Please create your User ID & Password





Contact Information











I have read the Karger Terms and Conditions and agree.

To view the fulltext, please log in

To view the pdf, please log in

Abstract

Background: In the published studies on the efficacy of the topical immunomodulator pimecrolimus, different eczema scores were used, and the impact on morphological key signs of eczema was not analysed. Objective: To compare the influence of pimecrolimus cream 1% on different standard eczema scores in infants with atopic dermatitis and to analyse the impact of treatment on the individual morphological key signs of eczema. Methods: Pimecrolimus cream 1% (n = 129) or double-blind vehicle control (n = 66) was administered for 4 weeks. The Eczema Area and Severity Index (EASI), Investigators’ Global Assessment (IGA) and Scoring Atopic Dermatitis Index (SCORAD) were determined and were correlated with each other. Results: Following treatment with pimecrolimus, the EASI, IGA and SCORAD were significantly reduced on day 29 as compared with the vehicle group (p < 0.001, p < 0.001, p = 0.002, respectively). There was a close correlation between EASI, IGA and SCORAD. The single parameters of the EASI were already significantly decreased by day 4 in the pimecrolimus group as compared to vehicle (each p < 0.001). Conclusion: Treatment with pimecrolimus 1% cream leads to a rapid improvement of all morphological signs of eczema. The close correlation of different scores was shown for the first time.



Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

References

  1. Administration UFaD: Guidance for Industry. E6 good clinical practice: Consolidated guidance. 1997, vol 10, pp 25691–25709.
  2. Bieber T, de la Salle H, Wollenberg A, Hakimi J, Chizzonite R, Ring J, et al: Human epidermal Langerhans cells express the high affinity receptor for immunoglobulin E (FcεRI). J Exp Med 1992;175:1285–1290.
  3. Breuer K, Häussler S, Kapp A, Werfel T: Staphylococcus aureus: Colonizing features and influence of an antibacterial treatment in adults with atopic dermatitis. Br J Dermatol 2002;147:55–61.
  4. Breuer K, Heratizadeh A, Wulf A, Baumann U, Constien A, Tetau D, Kapp A, Werfel T: Late eczematous reactions to food in children with atopic dermatitis. Clin Exp Allergy 2004;34:817–824.
  5. Bruijnzeel PL, Kuijper PH, Kapp A, Warringa RA, Betz S, Bruijnzeel-Koomen CA: The involvement of eosinophils in the patch test reaction to aeroallergens in atopic dermatitis: Its relevance for the pathogenesis of atopic dermatitis. Clin Exp Allergy 1993;23:97–109.
  6. Eichenfield LF, Lucky AW, Boguniewicz M, Langley R, Cherill R, Marshall K, et al: Safety and efficacy of pimecrolimus (ASM 981) cream 1% in the treatment of mild and moderate atopic dermatitis in children and adolescents. J Am Acad Dermatol 2002;138:495–504.
  7. Emerson RM, Williams HC, Allen BR: What is the cost of atopic dermatitis in preschool children? Br J Dermatol 2001;143:514–522.
  8. Feiwel M, Kelly WF: Adrenal unresponsiveness associated with clobetasol propionate. Lancet 1974;2:112–113.
  9. Grassberger M, Baumruker T, Enz A, Hiestand P, Hultsch T, Kalth F, et al: A novel anti-inflammatory drug, SDZ ASM 981, for the treatment of skin diseases: In vitro pharmacology. Br J Dermatol 1999;141:264–273.
  10. Grewe M, Gyufko K, Schöpf E, Krutmann J: Lesional expression of interferon-γ in atopic eczema. Lancet 1994;343:25–26.
  11. Hanifin JM, Thurston M, Omoto M, Cherill R, Tofte SJ, Graeber M: The eczema area and severity index (EASI): Assessment of reliability in atopic dermatitis. EASI Evaluator Group. Exp Dermatol 2001;10:11–18.
  12. Hill CJ, Rosenberg A: Adverse effects from topical corticosteroids. Cutis 1978;21:624–648.
  13. Ho V, Gupta A, Kaufmann R, Todd G, Vanaclocha F, Takaoka R, et al: Safety and efficacy of nonsteroid pimecrolimus cream 1% in the treatment of atopic dermatitis in infants. J Pediatr 2003;142:155–162.
  14. Kapp A, Papp K, Bingham A, Folster-Holst R, Ortonne JP, Potter P, et al: Long-term management of atopic dermatitis in infants with topical pimecrolimus, a nonsteroid anti-inflammatory drug. J Allergy Clin Immunol 2002;110:277–284.
  15. Kaufmann R, Fölster-Holst R, Höger P, Thaci D, Löffler H, Staab D, et al: Onset of action of pimecrolimus cream 1% in the treatment of atopic eczema in infants: A multicenter, randomized trial. J Allergy Clin Immunol, in press.
  16. Kunz B, Oranje AP, Labreze L, Ring J, Taïeb A: Clinical validation and guidelines for the SCORAD index: Consensus report of the European Task Force on Atopic Dermatitis. Dermatology 1997;195:10–19.
  17. Meingassner JG, Grassberger M, Fahrngruber H, Moore HD, Schuurmann H, Stütz A: A novel anti-inflammatory drug, SDZ ASM 981, for the topical and oral treatment of skin diseases: In vivo pharmacology. Br J Dermatol 1997;137:568–576.
  18. Meurer M, Folster-Holst R, Wozel G, Weidinger G, Junger M, Brautigam M: Pimecrolimus cream in the long-term management of atopic dermatitis in adults: A six-month study. Dermatology 2002;205:271–277.
  19. Mudde GC, von Reijsen FC, Boland GJ, Gast GC, Bruijnzeel PL, Bruijnzeel-Koomen CA: Allergen presentation by epidermal Langerhans cells from patients with atopic dermatitis is mediated by IgE. Immunology 1990;69:335–341.
  20. Queille-Roussel C, Paul C, Duteil L, Lefebvre MC, Rapatz G, Zagula M, et al: The new topical ascomycin derivative SDZ ASM 981 does not induce skin atrophy when applied to normal skin for 4 weeks: A randomized, double-blind controlled study. Br J Dermatol 2001;144:507–513.
  21. Sager N, Feldmann A, Schilling G, Kreitsch P, Neumann C: House dust mite-specific T cells in the skin of subjects with atopic dermatitis: Frequency and lymphokine profile in the allergen patch test. J Allergy Clin Immunol 1992;89:801–810.
  22. Saurat JH: Systemic side-effects of topical preparation in children. Sem Hop 1982;58:1643–1649.
  23. Schultz Larsen F, Thomas T, Svensson A: The occurrence of atopic dermatitis in north Europe: An international questionnaire study. J Am Acad Dermatol 1996;34:760–764.
  24. Seymour JL, Keswick BH, Hanifin JM, Jordan WP, Milligan MC: Clinical effects of diaper types on the skin of normal infants and infants with atopic dermatitis. J Am Acad Dermatol 1987;17:988–997.
  25. Tanaka Y, Anan S, Yoshida H: Immunohistochemical studies in mite-induced patch test site in atopic dermatitis. J Dermatol Sci 1990;1:361–368.
  26. Thepen T, Langeveld-Wiltschut EG, van Reijsen FC, van Wichen CF, van Reijsen FC, Mudde GC, et al: Bi-phasic response against aeroallergen in atopic dermatitis showing a switch from initial TH2 response into a TH1 response in situ. J Allergy Clin Immunol 1996;97:828–837.
  27. Wahn U, Bos JD, Goodfield M, Caputo R, Papp K, Manjra A, et al: Efficacy and safety of pimecrolimus cream in the long-term management of atopic dermatitis in children. Pediatrics 2002;110:1–8.
  28. Werfel T, Kapp A: Environmental and other major provocation factors in atopic dermatitis. Allergy 1998;53:731–739.
  29. Werfel T, Morita A, Grewe M, Renz H, Wahn U, Krutmann J, et al: Allergen-specificity of skin-infiltrating T-cells is not restricted to a type 2 cytokine pattern in chronic skin lesions of atopic dermatitis. J Invest Dermatol 1996;107:871–876.
  30. Williams HC: Is the prevalence of atopic dermatitis increasing? Clin Exp Dermatol 1992;17:385–391.
  31. Zuberbier T, Chong SU, Grunow K, Guhl S, Welker P, Grassberger M, et al: The ascomycin macrolactam pimecrolimus (Elidel, SDZ ASM 981) is a potent inhibitor of mediator release from human dermal mast cells and peripheral blood basophils. J Allergy Clin Immunol 2001;108:275–280.


Pay-per-View Options
Direct payment This item at the regular price: USD 38.00
Payment from account With a Karger Pay-per-View account (down payment USD 150) you profit from a special rate for this and other single items.
This item at the discounted price: USD 26.50